3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Rectal Neoplasms
10
Leukemia, Myeloid, Acute
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Leukemia
2
Thrombocythemia, Essential
1
Radiation Injuries
1
Primary Myelofibrosis
1
Postoperative Complications
1
Polycythemia Vera
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Lymphoma, B-Cell
1
Low Anterior Resection Syndrome
1
Leukemia, Myelomonocytic, Chronic
1
Hyperthermia
1
Fatigue
1
Esophageal Squamous Cell Carcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
Filgrastim
13
Peripheral Blood Stem Cell Transplantation
10
Melphalan
9
Ifosfamide
9
Etoposide
9
Cyclophosphamide
8
Thiotepa
6
Carboplatin
6
Busulfan
6
Radiotherapy
5
Doxorubicin
5
Vincristine
3
Topotecan
3
Temozolomide
3
Docetaxel
3
trioctyl phosphine oxide
2
temsirolimus
2
etoposide phosphate
2
Transplantation
2
Surgical Procedures, Operative
2
Stem Cell Transplantation
2
Radiotherapy, Intensity-Modulated
2
Microarray Analysis
2
Mesna
2
Granulocyte Colony-Stimulating Factor
2
Gemcitabine
2
Dexrazoxane
2
Cisplatin
2
Bone Marrow Transplantation
2
Amifostine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neuroectodermal Tumors, Primitive, Peripheral
×
Consolidation Chemotherapy
×
Clear all
NCT03011528
2025-11-21
CombinaiR3
Institut Curie
Phase 2
Completed
45 enrolled